PDF herunterladen
Semin intervent Radiol 2021; 38(04): 438-444
DOI: 10.1055/s-0041-1735526
Review Article

Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies

Joseph Ray Ness
1   Division of Diagnostic Radiology, Department of Radiology, Loyola University Medical Center, Maywood, Illinois
,
Christopher Molvar
1   Division of Diagnostic Radiology, Department of Radiology, Loyola University Medical Center, Maywood, Illinois
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Intrahepatic cholangiocarcinoma is the second most common primary hepatic malignancy and poses a therapeutic challenge owing to its late-stage presentation and treatment-resistant outcomes. Most patients are diagnosed with locally advanced, unresectable disease and are treated with a combination of systemic and local regional therapies. Transarterial radioembolization offers a survival benefit and a favorable side effect profile, with a growing body of evidence to support its use. Herein, we review patient selection and detail outcomes of radioembolization for intrahepatic cholangiocarcinoma, together with mention of competing treatments.

Keywords

intrahepatic cholangiocarcinoma - yttrium-90 - local regional therapy - radioembolization - interventional radiology


Publikationsverlauf

Artikel online veröffentlicht:
07. Oktober 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Banales JM, Cardinale V, Carpino G. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13 (05) 261-280
    CrossrefPubMedGoogle Scholar
  • 2 Banales JM, Marin JJG, Lamarca A. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17 (09) 557-588
    CrossrefPubMedGoogle Scholar
  • 3 Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci 2015; 22 (02) 94-100
    CrossrefPubMedGoogle Scholar
  • 4 Bertuccio P, Malvezzi M, Carioli G. et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71 (01) 104-114
    CrossrefPubMedGoogle Scholar
  • 5 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int 2019; 39 (Suppl. 01) 19-31
    CrossrefPubMedGoogle Scholar
  • 6 Bagante F, Gamblin TC, Pawlik TM. Cholangiocarcinoma risk factors and the potential role of aspirin. Hepatology 2016; 64 (03) 708-710
    CrossrefPubMedGoogle Scholar
  • 7 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020; 72 (01) 95-103
    CrossrefPubMedGoogle Scholar
  • 8 Shin HR, Oh JK, Lim MK. et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci 2010; 25 (07) 1011-1016
    CrossrefPubMedGoogle Scholar
  • 9 Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am 2019; 99 (02) 315-335
    CrossrefPubMedGoogle Scholar
  • 10 Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol 2017; 95: 349-361
    CrossrefPubMedGoogle Scholar
  • 11 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60 (06) 1268-1289
    CrossrefPubMedGoogle Scholar
  • 12 Hyder O, Hatzaras I, Sotiropoulos GC. et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153 (06) 811-818
    CrossrefPubMedGoogle Scholar
  • 13 Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15 (02) 95-111
    CrossrefPubMedGoogle Scholar
  • 14 Bartolini I, Risaliti M, Fortuna L. et al. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020; 54 (03) 263-271
    CrossrefPubMedGoogle Scholar
  • 15 Khuntikeo N, Koonmee S, Sa-Ngiamwibool P. et al. A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening program compared to walk-in patients. HPB (Oxford) 2020; 22 (06) 874-883
    CrossrefPubMedGoogle Scholar
  • 16 Yang CM, Shu J. Cholangiocarcinoma evaluation via imaging and artificial intelligence. Oncology 2021; 99 (02) 72-83
    CrossrefPubMedGoogle Scholar
  • 17 Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 2018; 288 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 18 Chung YE, Kim MJ, Park YN. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29 (03) 683-700
    CrossrefPubMedGoogle Scholar
  • 19 Inchingolo R, Maino C, Gatti M. et al. Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma. World J Gastroenterol 2020; 26 (29) 4261-4271
    CrossrefPubMedGoogle Scholar
  • 20 Huang X, Yang J, Li J, Xiong Y. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis. Medicine (Baltimore) 2020; 99 (35) e20932
    CrossrefPubMedGoogle Scholar
  • 21 Kao YH, Steinberg JD, Tay YS. et al. Post-radioembolization yttrium-90 PET/CT - part 1: diagnostic reporting. EJNMMI Res 2013; 3 (01) 56
    CrossrefPubMedGoogle Scholar
  • 22 Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 2013; 34 (04) 219-228
    CrossrefPubMedGoogle Scholar
  • 23 Sasaki K, Margonis GA, Andreatos N. et al. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford) 2018; 20 (10) 956-965
    CrossrefPubMedGoogle Scholar
  • 24 Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Linchuang Zhongliuxue Zazhi 2018; 7 (05) 52
    PubMedGoogle Scholar
  • 25 Cercek A, Boerner T, Tan BR. et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020; 6 (01) 60-67
    CrossrefPubMedGoogle Scholar
  • 26 Dodson RM, Weiss MJ, Cosgrove D. et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013; 217 (04) 736-750.e4
    CrossrefPubMedGoogle Scholar
  • 27 Goere D, Wagholikar GD, Pessaux P. et al. Utility of staging laparoscopy in subsets of biliary cancers : laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006; 20 (05) 721-725
    CrossrefPubMedGoogle Scholar
  • 28 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
    CrossrefPubMedGoogle Scholar
  • 29 Zhu H, Wang L, Wang M. et al. Prognostic value of resection margin length after surgical resection for intrahepatic cholangiocarcinoma. Am J Surg 2020 S0002-9610(20)30800-X
    PubMedGoogle Scholar
  • 30 Watanabe Y, Matsuyama Y, Izumi N. et al. Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: a nationwide survey of the Liver Cancer Study Group of Japan. Surgery 2020; 167 (05) 793-802
    CrossrefPubMedGoogle Scholar
  • 31 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018; 24 (02) 294-303
    CrossrefPubMedGoogle Scholar
  • 32 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al; iCCA International Consortium. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64 (04) 1178-1188
    CrossrefPubMedGoogle Scholar
  • 33 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 34 Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26 (07) 943-948
    CrossrefPubMedGoogle Scholar
  • 35 Díaz-González Á, Vilana R, Bianchi L. et al. Thermal ablation for intrahepatic cholangiocarcinoma in cirrhosis: safety and efficacy in non-surgical patients. J Vasc Interv Radiol 2020; 31 (05) 710-719
    CrossrefPubMedGoogle Scholar
  • 36 Kis B, El-Haddad G, Sheth RA. et al. Liver-directed therapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Contr 2017; 24 (03) 1073274817729244
    PubMedGoogle Scholar
  • 37 Kim YI, Park JW, Kim BH. et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013; 8: 292
    CrossrefPubMedGoogle Scholar
  • 38 Currie BM, Soulen MC. Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017; 34 (02) 92-100
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015; 12 (08) 481-489
    CrossrefPubMedGoogle Scholar
  • 40 Ray Jr CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (08) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 41 Riby D, Mazzotta AD, Bergeat D. et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020; 27 (10) 3729-3737
    CrossrefPubMedGoogle Scholar
  • 42 Hoffmann RT, Paprottka PM, Schön A. et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012; 35 (01) 105-116
    CrossrefPubMedGoogle Scholar
  • 43 Mouli S, Memon K, Baker T. et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013; 24 (08) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 44 Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-naïve patients. Cardiovasc Intervent Radiol 2018; 41 (05) 744-752
    CrossrefPubMedGoogle Scholar
  • 45 White J, Carolan-Rees G, Dale M. et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study. J Vasc Interv Radiol 2019; 30 (08) 1185-1192
    CrossrefPubMedGoogle Scholar
  • 46 Rafi S, Piduru SM, El-Rayes B. et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013; 36 (02) 440-448
    CrossrefPubMedGoogle Scholar
  • 47 Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13 (11) 1163-1166
    CrossrefPubMedGoogle Scholar
  • 48 Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (08) 965-968
    CrossrefPubMedGoogle Scholar
  • 49 Mascarenhas N, Ryu RK, Salem R. Hepatic radioembolization complicated by abscess. Semin Intervent Radiol 2011; 28 (02) 222-225
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 50 Boehm LM, Jayakrishnan TT, Miura JT. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111 (02) 213-220
    CrossrefPubMedGoogle Scholar
  • 51 Saini A, Wallace A, Alzubaidi S. et al. History and evolution of yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med 2019; 8 (01) E55
    CrossrefPubMedGoogle Scholar
  • 52 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013; 58 (06) 2188-2197
    CrossrefPubMedGoogle Scholar
  • 53 Sato K, Lewandowski RJ, Bui JT. et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29 (04) 522-529
    CrossrefPubMedGoogle Scholar
  • 54 Ibrahim SM, Mulcahy MF, Lewandowski RJ. et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113 (08) 2119-2128
    CrossrefPubMedGoogle Scholar
  • 55 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (01) 120-127
    CrossrefPubMedGoogle Scholar
  • 56 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. OncoTargets Ther 2019; 12: 4489-4498
    CrossrefPubMedGoogle Scholar
  • 57 Gangi A, Shah J, Hatfield N. et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol 2018; 29 (08) 1101-1108
    CrossrefPubMedGoogle Scholar
  • 58 Buettner S, Braat AJAT, Margonis GA. et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol 2020; 31 (07) 1035-1043.e2
    CrossrefPubMedGoogle Scholar
  • 59 Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. 90Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: glass versus resin microspheres. Nucl Med Biol 2018; 59: 22-28
    CrossrefPubMedGoogle Scholar
  • 60 Manceau V, Palard X, Rolland Y. et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018; 45 (10) 1731-1741
    CrossrefPubMedGoogle Scholar
  • 61 Edeline J, Du FL, Rayar M. et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med 2015; 40 (11) 851-855
    CrossrefPubMedGoogle Scholar
  • 62 Bargellini I, Mosconi C, Pizzi G. et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 2020; 43 (09) 1305-1314
    CrossrefPubMedGoogle Scholar
  • 63 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2019; (epub ahead of print) DOI: 10.1001/jamaoncol.2019.3702.
    CrossrefPubMedGoogle Scholar
  • 64 Garin E, Lenoir L, Edeline J. et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging 2013; 40 (07) 1057-1068
    CrossrefPubMedGoogle Scholar
  • 65 Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med 2019; 49 (03) 237-243
    CrossrefPubMedGoogle Scholar
  • 66 Elschot M, Nijsen JF, Lam MG. et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging 2014; 41 (10) 1965-1975
    CrossrefPubMedGoogle Scholar
  • 67 Smits ML, Nijsen JF, van den Bosch MA. et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res 2010; 29 (01) 70
    CrossrefPubMedGoogle Scholar
  • 68 Depalo T, Boni G, Ghinolfi D. et al. Potential benefits of holmium-166 radioembolization as a neoadjuvant treatment of intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2021; 44 (02) 345-347
    CrossrefPubMedGoogle Scholar